🧬 BDNF Extraction Viewer

Извлечено: 997 / 997 (100.0%) Средняя confidence: 0.13
← Назад к списку

Investigating brain-derived neurotrophic factor (BDNF) changes in three main rodent models of autism spectrum disorder (ASD): a systematic review.

PMID: 41746531 · DOI: 10.1007/s12640-026-00787-1 · Neurotoxicity research, 2026 · Marzieh Jalalian-Javadpour, Mahdi Khaledian, Hamed Moradi, Hamidreza Behnoud, Mandana Sajjadi, Batool Ghorbani Yekta, Sa
📄 Abstract

Autism spectrum disorder (ASD) is a neurodevelopmental disorder characterized by social impairments, and repetitive and aggressive behaviors. The pathophysiology of ASD still remains unclear, while the population with ASD is 1/36 in children in the USA in 2024. Evidence suggests a wide range of inconsistent changes in brain-derived neurotrophic factor (BDNF), the most important neurotrophin in the central nervous system, in ASD. The present systematic review investigated studies that examined BDNF levels in three main ASD-like models in rodents [induced by valproic acid (VPA) and propionic acid (PPA), and in the BTBR mouse strain] in accord with PRISMA guidelines and in PubMed database. Forty-two studies were included. Most studies used male rats/mice. The results showed ASD model induced by VPA often leads to decreased BDNF, although unchanged or increased BDNF levels were also reported. ASD model induced by PPA leads to both increased and decreased BDNF. BDNF changes in BTBR mouse strain were also inconsistent. We found that the type of molecular assay appears to be important in evaluating BDNF. Also, few evidence showed a role for postnatal day and sex difference in BDNF changes in ASD-like rodent models. In addition, some studies have shown the potential role of the brain region in BDNF changes in different ASD-like models. In conclusion, it was suggested that inconsistencies in BDNF changes in rodent models of ASD may be related to the type of the molecular assay, the brain region, ASD model, sex, or even the postnatal day. However, evidence is still insufficient.

Confidence: 0.16 · 6 полей извлечено
Идентификация (6 полей)
Target
BDNF
1.00
Alt. target
brain-derived neurotrophic factor
1.00
Protein family
neurotrophin
0.90
Functional class
growth factor
0.80
Subcellular loc.
0.00
Isoforms (metab/obesity)
0.00
Механизм действия (21 полей)
Mechanism
0.00
Mutations (obesity/lean)
0.00
Activity (obesity)
0.00
Activity temporal
0.00
Energy balance
0.00
Appetite
0.00
Fat metabolism
0.00
Lipolysis
0.00
Thermogenesis
0.00
Muscle metabolism
0.00
Inflammation
0.00
Glucose metabolism
0.00
AA metabolism
0.00
Hormonal pathways
0.00
Cell death
0.00
Adipocyte fibrosis
0.00
Upstream (biochem)
0.00
Upstream (physiol)
0.00
Downstream (biochem)
0.00
Downstream (physiol)
0.00
PTMs
0.00
Экспрессия (8 полей)
Tissue expression
0.00
In vitro
0.00
In vivo
The systematic review examined BDNF levels in three rodent models of ASD: valproic acid (VPA) induced, propionic acid (PPA) induced, and BTBR mouse strain. Results showed VPA model often leads to decreased BDNF, though unchanged or increased levels also reported. PPA model leads to both increased and decreased BDNF. BTBR mouse strain showed inconsistent BDNF changes. Factors influencing BDNF changes include molecular assay type, brain region, sex, and postnatal day.
0.95
In silico
0.00
Genetic association
0.00
Ex vivo
0.00
Animal model
Rodent models of ASD: valproic acid (VPA) induced, propionic acid (PPA) induced, and BTBR mouse strain. Most studies used male rats/mice.
0.95
Diet/model
0.00
Клиника (11 полей)